Lateral Sclerosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LTR001 MIFTS: 60	Lateral Sclerosis Categories: Genetic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis ¹² ¹⁵ ⁷⁴

Primary Lateral Sclerosis ¹² ⁷⁷ ⁵⁴ ⁵⁵ ⁵⁶

Adult-Onset Primary Lateral Sclerosis ¹² ⁵⁴

Motor Neuron Disease ⁴⁵ ⁷⁴

Adult-Onset Pls ⁵⁴

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:230

ICD9CM ³⁶ 335.24

MeSH ⁴⁵ D016472

NCIt ⁵¹ C129933

SNOMED-CT ⁶⁹ 81211007

ICD10 ³⁴ G12.23

UMLS ⁷⁴ C0085084 C0154682

Sources

Summaries for Lateral Sclerosis

NIH Rare Diseases : ⁵⁴ Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, adult, 1 and amyotrophic lateral sclerosis 2, juvenile, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (Alsin Rho Guanine Nucleotide Exchange Factor ALS2), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : ¹² A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : ⁷⁷ Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Sources

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile

Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)

#	Related Disease	Score	Top Affiliating Genes
1	primary lateral sclerosis, adult, 1	34.6	ALS2 SOD1
2	amyotrophic lateral sclerosis 2, juvenile	34.6	ALS2 SOD1
3	amyotrophic lateral sclerosis 4, juvenile	34.5	ALS2 SETX
4	amyotrophic lateral sclerosis type 6	34.5	ALS2 FUS SETX TARDBP
5	amyotrophic lateral sclerosis 16, juvenile	34.4	ALS2 SIGMAR1 SOD1
6	amyotrophic lateral sclerosis 18	34.4	C9orf72 FUS SOD1 TARDBP
7	amyotrophic lateral sclerosis 20	34.3	ALS2 HNRNPA1
8	juvenile amyotrophic lateral sclerosis	34.3	ALS2 FUS SETX SIGMAR1
9	frontotemporal dementia and/or amyotrophic lateral sclerosis 1	34.3	C9orf72 CHCHD10 FUS TARDBP UBQLN2 VCP
10	amyotrophic lateral sclerosis 10 with or without frontotemporal dementia	34.1	ALS2 ANG FIG4 FUS SETX TARDBP
11	amyotrophic lateral sclerosis 11	34.1	ALS2 ANG FIG4 FUS SETX TARDBP
12	amyotrophic lateral sclerosis 9	34.1	ALS2 ANG FIG4 FUS SETX TARDBP
13	amyotrophic lateral sclerosis type 14	34.0	FUS TARDBP UBQLN2 VAPB VCP
14	amyotrophic lateral sclerosis 21	34.0	C9orf72 FUS SETX SOD1 TARDBP VAPB
15	amyotrophic lateral sclerosis 7	34.0	ALS2 ANG FIG4 FUS SETX TARDBP
16	frontotemporal dementia	32.8	C9orf72 CHCHD10 FUS HNRNPA1 NEFH SOD1
17	progressive muscular atrophy	32.5	C9orf72 TARDBP
18	distal hereditary motor neuropathies	32.1	DCTN1 SETX
19	perry syndrome	32.0	C9orf72 DCTN1 TARDBP
20	motor neuron disease	31.8	ALS2 C9orf72 CHCHD10 DCTN1 FUS NEFH
21	amyotrophic lateral sclerosis 1	31.6	ALS2 ANG C9orf72 CHCHD10 DCTN1 FIG4
22	spinal muscular atrophy	30.7	CHCHD10 HNRNPA1 SIGMAR1 VAPB
23	dementia	30.6	C9orf72 CHCHD10 FUS HNRNPA1 TARDBP TRPM7
24	progressive non-fluent aphasia	30.3	C9orf72 VCP
25	brown-vialetto-van laere syndrome	30.2	ALS2 C9orf72 SOD1 TARDBP UBQLN2
26	charcot-marie-tooth disease	30.2	DCTN1 FIG4 NEFH SETX VCP
27	behavioral variant of frontotemporal dementia	30.1	C9orf72 VCP
28	semantic dementia	30.0	C9orf72 TARDBP
29	primary lateral sclerosis, juvenile	12.7
30	madras motor neuron disease	12.7
31	amyotrophic lateral sclerosis-parkinsonism/dementia complex 1	12.7
32	amyotrophic lateral sclerosis 8	12.7
33	amyotrophic lateral sclerosis 19	12.6
34	amyotrophic lateral sclerosis 17	12.6
35	amyotrophic lateral sclerosis 6 with or without frontotemporal dementia	12.6
36	amyotrophic lateral sclerosis 14 with or without frontotemporal dementia	12.6
37	frontotemporal dementia and/or amyotrophic lateral sclerosis 2	12.6
38	amyotrophic lateral sclerosis 12	12.5
39	amyotrophic lateral sclerosis 3	12.5
40	frontotemporal dementia and/or amyotrophic lateral sclerosis 3	12.5
41	frontotemporal dementia and/or amyotrophic lateral sclerosis 4	12.5
42	amyotrophic lateral sclerosis 15 with or without frontotemporal dementia	12.5
43	amyotrophic lateral sclerosis 23	12.5
44	amyotrophic lateral sclerosis type 5	12.5
45	amyotrophic lateral sclerosis 25	12.5
46	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia	12.5
47	amyotrophic lateral sclerosis 24	12.5
48	amyotrophic lateral sclerosis 5, juvenile	12.5
49	amyotrophic lateral sclerosis, juvenile, with dementia	12.4
50	amyotrophic lateral sclerosis type 15	12.4

Graphical network of the top 20 diseases related to Lateral Sclerosis:

Sources

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:

ataxia, myoclonus, hemiplegia, muscular fasciculation

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	shRNA abundance <= 50%	GR00343-S	9.32	ANG FUS HNRNPA1 RNF19A SETX SOD1

MGI Mouse Phenotypes related to Lateral Sclerosis:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.03	ALS2 C9orf72 DCTN1 FIG4 NEFH RNF19A
2	cellular	MP:0005384	9.9	C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3	muscle	MP:0005369	9.5	ALS2 DCTN1 FIG4 SOD1 TARDBP VAPB
4	nervous system	MP:0003631	9.4	ALS2 C9orf72 DCTN1 FIG4 NEFH PRPH

Sources

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 338)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Riluzole

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

1744-22-5

5070

Mexiletine

Approved, Investigational

Phase 4,Phase 2

31828-71-4

4178

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Neuroprotective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Anticonvulsants

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Excitatory Amino Acids

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Protective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Excitatory Amino Acid Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Anti-Arrhythmia Agents

Phase 4,Phase 3,Phase 2,Phase 1

Sodium Channel Blockers

Phase 4,Phase 3,Phase 2,Phase 1

Diuretics, Potassium Sparing

Phase 4,Phase 3,Phase 2,Phase 1

Central Nervous System Stimulants

Phase 4,Phase 1

Cytochrome P-450 CYP3A Inducers

Phase 4

Wakefulness-Promoting Agents

Phase 4

Olanzapine

Approved, Investigational

Phase 2, Phase 3

132539-06-1

4585

Iron

Approved, Experimental

Phase 2, Phase 3,Not Applicable

7439-89-6, 15438-31-0

23925 27284

Lithium carbonate

Approved

Phase 2, Phase 3

554-13-2

Methylcobalamin

Approved, Experimental, Investigational

Phase 2, Phase 3,Phase 3

13422-55-4

Edaravone

Approved, Investigational

Phase 3,Phase 2

89-25-8

70335

Memantine

Approved, Investigational

Phase 2, Phase 3

19982-08-2

4054

Dopamine

Approved

Phase 2, Phase 3,Phase 3,Phase 1

62-31-7, 51-61-6

681

Hydroxocobalamin

Approved

Phase 2, Phase 3,Phase 3

13422-51-0

11953898 15589840

Zinc

Approved, Investigational

Phase 3,Phase 1,Phase 2

7440-66-6

32051

Mecasermin

Approved, Investigational

Phase 3

68562-41-4

Sargramostim

Approved, Investigational

Phase 2, Phase 3,Not Applicable

123774-72-1, 83869-56-1

Lenograstim

Approved, Investigational

Phase 2, Phase 3,Not Applicable

135968-09-1

Pramipexole

Approved, Investigational

Phase 3,Phase 1,Phase 2

104632-26-0

119570 59868

Minocycline

Approved, Investigational

Phase 3,Phase 2

10118-90-8

5281021

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

14986

Valproic Acid

Approved, Investigational

Phase 3,Phase 2

99-66-1

3121

Ceftriaxone

Approved

Phase 3

73384-59-5

5479530 5361919

Acetylcholine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Not Applicable

51-84-3

187

Guaifenesin

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Phase 1

93-14-1

3516

Dextromethorphan

Approved

Phase 3,Phase 2,Phase 1

125-71-3

5362449 5360696

Quinidine

Approved, Investigational

Phase 3,Phase 2,Phase 1

56-54-2

441074

Citalopram

Approved

Phase 3

59729-33-8

2771

Sodium Citrate

Approved, Investigational

Phase 3,Phase 2

68-04-2

Deferiprone

Approved

Phase 2, Phase 3,Not Applicable

30652-11-0

2972

Creatine

Approved, Investigational, Nutraceutical

Phase 3,Phase 2

57-00-1

586

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1

59-30-3

6037

Cyanocobalamin

Approved, Nutraceutical

Phase 2, Phase 3,Phase 3

68-19-9

44176380

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 3

59-02-9

14985

Coenzyme Q10

Approved, Investigational, Nutraceutical

Phase 3,Phase 2

303-98-0

5281915

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

77-92-9

311

Cobalamin

Experimental

Phase 2, Phase 3,Phase 3

13408-78-1

6857388

Tocotrienol

Investigational

Phase 3

6829-55-6

Nabiximols

Investigational

Phase 2, Phase 3

56575-23-6

Taurochenodeoxycholic acid

Experimental

Phase 3,Phase 2

516-35-8

387316

Tauroursodeoxycholic acid

Experimental, Investigational

Phase 3,Phase 2

14605-22-2

12443252

Interventional clinical trials:

(show top 50) (show all 515)

#	Name	Status	NCT ID	Phase	Drugs
1	Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis	Unknown status	NCT00560287	Phase 4
2	CARE Canadian ALS Riluzole Evaluation	Completed	NCT00542412	Phase 4	Riluzole
3	Mexiletine for the Treatment of Muscle Cramps in ALS	Completed	NCT01811355	Phase 4	Mexiletine;Placebo
4	Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)	Completed	NCT00613899	Phase 4
5	Modafinil for Treatment of Fatigue in ALS Patients	Completed	NCT00614926	Phase 4	Modafinil;Placebo
6	MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study	Completed	NCT03226119	Phase 4
7	Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)	Unknown status	NCT00876772	Phase 2, Phase 3	Olanzapine
8	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	Unknown status	NCT00069186	Phase 3	Creatine Monohydrate
9	Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT02588677	Phase 2, Phase 3	Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
10	A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00445172	Phase 2, Phase 3	E0302 (mecobalamin)
11	Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis	Completed	NCT01492686	Phase 3	MCI-186;Placebo;MCI-186 in open label phase
12	Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)	Completed	NCT00353665	Phase 2, Phase 3	Memantine (Ebixa);riluzole;Placebo
13	A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00444613	Phase 2, Phase 3	E0302 (mecobalamin);E0302 (mecobalamin);Placebo
14	Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis	Completed	NCT00706147	Phase 2, Phase 3	Arimoclomol;Placebo
15	Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00424463	Phase 3	MCI-186;Placebo of MCI-186
16	Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial	Completed	NCT00035815	Phase 3	Insulin like growth factor, type 1;Placebo
17	The Effect of GCSF in the Treatment of ALS Patients	Completed	NCT01825551	Phase 2, Phase 3	Granulocyte Colony Stimulating Factor;Placebo
18	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00330681	Phase 3	MCI-186;Placebo of MCI-186
19	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III	Completed	NCT00415519	Phase 3	MCI-186;Placebo of MCI-186
20	Phase 3 Study of Dexpramipexole in ALS	Completed	NCT01281189	Phase 3	Dexpramipexole;Placebo
21	Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT01933321	Phase 2, Phase 3
22	Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis	Completed	NCT00833820	Phase 2, Phase 3
23	Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls	Completed	NCT01160263	Phase 3	SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
24	Minocycline to Treat Amyotrophic Lateral Sclerosis	Completed	NCT00047723	Phase 3	minocycline
25	Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS	Completed	NCT00372879	Phase 3
26	Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis	Completed	NCT00136110	Phase 3	Sodium Valproate
27	Clinical Trial Ceftriaxone in Subjects With ALS	Completed	NCT00349622	Phase 3	ceftriaxone
28	Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00125203	Phase 2, Phase 3	Botulinum toxin type B (Myobloc)
29	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS	Completed	NCT00868166	Phase 3	Olesoxime;Placebo Comparator;Riluzole
30	A Study for Patients Who Completed VITALITY-ALS (CY 4031)	Completed	NCT02936635	Phase 3	tirasemtiv
31	Safety Extension Study of TRO19622 in ALS	Completed	NCT01285583	Phase 2, Phase 3	TRO19622
32	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year	Completed	NCT02496767	Phase 3	tirasemtiv;Placebo tablets;Riluzole 50 MG
33	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS	Completed	NCT00021697	Phase 3	AVP-923
34	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	Completed	NCT00573443	Phase 3	dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
35	Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement	Completed	NCT00386464	Phase 2, Phase 3
36	Escitalopram (Lexapro) for Depression MS or ALS	Completed	NCT00965497	Phase 3	escitalopram
37	Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease	Completed	NCT01776970	Phase 2, Phase 3	Cannabis Sativa extract Oromucosal spray
38	Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)	Completed	NCT01257828	Phase 3	riluzole;Placebo medication
39	Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects	Completed	NCT01994109	Phase 3	MYOBLOC
40	Arimoclomol in Amyotropic Lateral Sclerosis	Recruiting	NCT03491462	Phase 3	Arimoclomol;Placebo oral capsule
41	Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease	Recruiting	NCT03690791	Phase 3	CannTrust CBD Oil (capsule);Placebo (capsule)
42	Clinical Trial of Ultra-high Dose Methylcobalamin for ALS	Recruiting	NCT03548311	Phase 3	methylcobalamin;saline solution
43	An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)	Recruiting	NCT02623699	Phase 3	BIIB067
44	Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS	Recruiting	NCT03800524	Phase 3	Tauroursodeoxycholic acid (TUDCA);Placebo
45	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	Recruiting	NCT03280056	Phase 3
46	Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS	Recruiting	NCT03505021	Phase 3	Levosimendan;Placebo for levosimendan
47	Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)	Recruiting	NCT03347344	Phase 3	Riluzole;Placebo
48	Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)	Active, not recruiting	NCT03272802	Phase 2, Phase 3	Edaravone;Riluzole
49	Long-Term Evaluation of BIIB067	Enrolling by invitation	NCT03070119	Phase 3	BIIB067
50	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis	Not yet recruiting	NCT03293069	Phase 2, Phase 3	Deferiprone;Placebo Oral Tablet

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Sources

Genetic Tests for Lateral Sclerosis

Sources

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

⁴²

Brain, Spinal Cord, Bone, Testes, Cortex, Skeletal Muscle, Bone Marrow

Sources

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 5305)

#	Title	Authors	Year
1	Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. ( 30740050 )	Prell T...Grosskreutz J	2019
2	Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis. ( 30565851 )	Ziff OJ...Patani R	2019
3	Assessing Anxiety and its correlates in Amyotrophic Lateral Sclerosis: the State-Trait Anxiety Inventory. ( 30897219 )	Siciliano M...Santangelo G	2019
4	Hereditary primary lateral sclerosis and progressive nonfluent aphasia. ( 30834979 )	Gazulla J...Berciano J	2019
5	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. ( 30859373 )	Fredi M...Zanella I	2019
6	A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: A rare co-occurrence of autism spectrum disorder and tremor. ( 30684766 )	Eura N...Aoki M	2019
7	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. ( 30911572 )	Ahmed RM...Kiernan MC	2019
8	HR23B pathology preferentially co-localizes with p62, pTDP-43 and poly-GA in C9ORF72-linked frontotemporal dementia and amyotrophic lateral sclerosis. ( 30867060 )	Riemslagh FW...Willemsen R	2019
9	Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. ( 30763568 )	Haukedal H...Freude K	2019
10	Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. ( 30791515 )	Imai Y...Hattori N	2019
11	Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )	Gkazi SA...Shaw CE	2019
12	Depression and risk of Cognitive Dysfunctions in Amyotrophic Lateral Sclerosis. ( 30712314 )	De Marchi F...Mazzini L	2019
13	A case of amyotrophic lateral sclerosis which was diagnosed with progressive dysphagia and muscle atrophy. ( 30631656 )	Komata T	2019
14	GABAB receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis. ( 30871492 )	Schumacher H...Pr?ss H	2019
15	Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS. ( 30635486 )	Geevasinga N...Vucic S	2019
16	VAPB depletion alters neuritogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked ALS. ( 30745341 )	Genevini P...Navone F	2019
17	Response to Letter to the Editor: "Amyotrophic lateral sclerosis and exposure to diesel exhaust in a Danish cohort". ( 30753256 )	Dickerson AS...Weisskopf MG	2019
18	High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. ( 30760645 )	Goutman SA...Feldman EL	2019
19	Muscle secretion of toxic factors, regulated by miR126-5p, facilitates motor neuron degeneration in amyotrophic lateral sclerosis. ( 30762002 )	Maimon R...Perlson E	2019
20	Corrigendum to "Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis" [Brain Research Bulletin 140 (2018) 318-333]. ( 30770039 )	Fogarty MJ	2019
21	Contact Sports as a Risk Factor for Amyotrophic Lateral Sclerosis: A Systematic Review. ( 30775214 )	Blecher R...Chapman JR	2019
22	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30782181 )	Lee JD...Woodruff TM	2019
23	Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. ( 30784318 )	Chen X...Shang H	2019
24	TDP-43: A KEY THERAPEUTIC TARGET BEYOND AMYOTROPHIC LATERAL SCLEROSIS. ( 30785719 )	Palomo V...Mart?nez A	2019
25	Smoking and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. ( 30786056 )	Zhan Y...Fang F	2019
26	Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis. ( 30789031 )	Thurn T...Anneser J	2019
27	Regional dynamics of the resting brain in amyotrophic lateral sclerosis using fALFF and ReHo analyses. ( 30793923 )	Bueno AP...Sato JR	2019
28	Tract integrity in amyotrophic lateral sclerosis: 6-month evaluation using MR diffusion tensor imaging. ( 30795741 )	Alruwaili AR...McCombe PA	2019
29	Excitability in somatosensory cortex correlates with motoric impairment in amyotrophic lateral sclerosis. ( 30798637 )	H?ffken O...Sczesny-Kaiser M	2019
30	Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807321 )	Fu LL...Cui LY	2019
31	Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807353 )	Fu LL...Cui LY	2019
32	Edaravone for the treatment of amyotrophic lateral sclerosis. ( 30810406 )	Yoshino H	2019
33	Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30811816 )	Bursch F...Petri S	2019
34	Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. ( 30811981 )	Cooper-Knock J...Shaw PJ	2019
35	A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. ( 30814647 )	Devos D...Pradat PF	2019
36	Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. ( 30816241 )	Camerino GM...Pierno S	2019
37	Psychological flexibility and attitudes toward evidence-based interventions by amyotrophic lateral sclerosis patients. ( 30828499 )	Pearlman JR...Thorsteinsson EB	2019
38	Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. ( 30837838 )	Prasad A...Patel BK	2019
39	Information-domain method for the quantification of the complexity of the sympathetic baroreflex regulation in healthy subjects and amyotrophic lateral sclerosis patients. ( 30840931 )	Cairo B...Porta A	2019
40	Amyotrophic Lateral Sclerosis: The Assessment of Inspiratory Muscle Failure. ( 30846202 )	Mart?nez-Llorens J...Bala?? Corber? A	2019
41	Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. ( 30846540 )	Ryan M...Hardiman O	2019
42	A near miss: Autonomic dysfunction in a 2% total burn surface area burn patient with ventilator-dependent amyotrophic lateral sclerosis. ( 30847184 )	King BBT...Wagner AL	2019
43	Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations. ( 30847648 )	Naruse H...Tsuji S	2019
44	Impaired short and long latency afferent inhibition in ALS. ( 30847934 )	Cengiz B...Kuruo?lu R	2019
45	Androgen receptor antagonism accelerates disease onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30849180 )	McLeod VM...Turner BJ	2019
46	Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. ( 30850472 )	Visser AE...Euro-MOTOR consortium	2019
47	Carboxyl-terminal modulator protein regulates Akt signaling during skeletal muscle atrophy in vitro and a mouse model of amyotrophic lateral sclerosis. ( 30850672 )	Wang J...Walker CL	2019
48	Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. ( 30855701 )	Barc K...Kuzma-Kozakiewicz M	2019
49	ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis. ( 30861116 )	Joshi AR...Lehmann HC	2019
50	Searching for Bacteria in Neural Tissue From Amyotrophic Lateral Sclerosis. ( 30863279 )	Alonso R...Carrasco L	2019

Sources

Genes for Lateral Sclerosis

Genes related to Lateral Sclerosis (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ALS2	Alsin Rho Guanine Nucleotide Exchange Factor ALS2	Protein Coding	90.18	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Pathways & Interactions Transcripts Variants (show sections)
2	SOD1	Superoxide Dismutase 1	Protein Coding	78.93	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Pathways & Interactions Variants (show sections)
3	NEFH	Neurofilament Heavy	Protein Coding	72.27	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions Functions Variants (show sections)
4	FUS	FUS RNA Binding Protein	Protein Coding	66.04	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
5	SETX	Senataxin	Protein Coding	65.26	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
6	SIGMAR1	Sigma Non-Opioid Intracellular Receptor 1	Protein Coding	62.5	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants localization (show sections)
7	VCP	Valosin Containing Protein	Protein Coding	62.47	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants localization (show sections)
8	HNRNPA1	Heterogeneous Nuclear Ribonucleoprotein A1	Protein Coding	56.33	GeneCards inferred via : Disorders Publications Summaries Proteins Variants (show sections)
9	C9orf72	C9orf72-SMCR8 Complex Subunit	Protein Coding	55.8	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
10	CHCHD10	Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10	Protein Coding	47.85	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
11	PRPH	Peripherin	Protein Coding	45.91	GeneCards inferred via : Publications Summaries Pathways & Interactions Variants (show sections)
12	TRPM7	Transient Receptor Potential Cation Channel Subfamily M Member 7	Protein Coding	45.28	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
13	TARDBP	TAR DNA Binding Protein	Protein Coding	45.19	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
14	RNF19A	Ring Finger Protein 19A, RBR E3 Ubiquitin Protein Ligase	Protein Coding	45.19	GeneCards inferred via : Publications Summaries Proteins localization (show sections)
15	VAPB	VAMP Associated Protein B And C	Protein Coding	43.82	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
16	DCTN1	Dynactin Subunit 1	Protein Coding	43.28	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
17	FIG4	FIG4 Phosphoinositide 5-Phosphatase	Protein Coding	43.19	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
18	UBQLN2	Ubiquilin 2	Protein Coding	42.7	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
19	ANG	Angiogenin	Protein Coding	41.95	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
20	FLACC1	Flagellum Associated Containing Coiled-Coil Domains 1	Protein Coding	35.95	GeneCards inferred via : Publications Gene name Proteins Transcripts (show sections)
21	ATXN2	Ataxin 2	Protein Coding	30.89	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries (show sections)
22	GRIA2	Glutamate Ionotropic Receptor AMPA Type Subunit 2	Protein Coding	30.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Pathways & Interactions (show sections)
23	SQSTM1	Sequestosome 1	Protein Coding	29.02	GeneCards inferred via : Disorders Publications Variants (show sections)
24	OPTN	Optineurin	Protein Coding	28.87	GeneCards inferred via : Disorders Publications Variants (show sections)
25	TBK1	TANK Binding Kinase 1	Protein Coding	28.45	GeneCards inferred via : Disorders Publications Variants (show sections)
26	MATR3	Matrin 3	Protein Coding	27.74	GeneCards inferred via : Disorders Publications Variants (show sections)
27	PFN1	Profilin 1	Protein Coding	27.26	GeneCards inferred via : Disorders Publications Variants (show sections)
28	LOC109504728	Chromosome 9 Open Reading Frame 72 Repeat Instability Region	Biological Region	27.11	GeneCards inferred via : Publications Gene name Summaries (show sections)
29	ANXA11	Annexin A11	Protein Coding	26.92	GeneCards inferred via : Disorders Publications Variants (show sections)
30	TUBA4A	Tubulin Alpha 4a	Protein Coding	26.84	GeneCards inferred via : Disorders Publications Variants (show sections)
31	KIF5A	Kinesin Family Member 5A	Protein Coding	26.82	GeneCards inferred via : Disorders Publications Variants (show sections)
32	SPG11	SPG11 Vesicle Trafficking Associated, Spatacsin	Protein Coding	26.64	GeneCards inferred via : Disorders Publications Variants (show sections)
33	MPP4	Membrane Palmitoylated Protein 4	Protein Coding	26.55	GeneCards inferred via : Publications Gene name Variants (show sections)

Sources

Variations for Lateral Sclerosis

Sources

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Sources

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ⁴	11.89	DCTN1 NEFH SIGMAR1 SOD1 TARDBP
2	Cytoskeleton remodeling Neurofilaments ²³ Show member pathways Cytoskeleton remodeling Keratin filaments ²³	11.37	DCTN1 NEFH PRPH
3	Amyotrophic lateral sclerosis (ALS) ³⁸ ¹ Show member pathways Pathogenesis of ALS ⁶⁵	10.98	ALS2 NEFH PRPH SOD1

Sources

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasmic vesicle	GO:0031410	9.72	ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2	neuronal cell body	GO:0043025	9.55	ALS2 ANG DCTN1 FUS SOD1
3	myelin sheath	GO:0043209	9.54	NEFH SOD1 VCP
4	lipid droplet	GO:0005811	9.43	FIG4 SIGMAR1 VCP
5	axon	GO:0030424	9.35	ALS2 C9orf72 DCTN1 NEFH SETX
6	growth cone	GO:0030426	9.02	ALS2 ANG C9orf72 SETX SIGMAR1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	locomotory behavior	GO:0007626	9.33	ALS2 FIG4 SOD1
2	regulation of autophagosome assembly	GO:2000785	8.96	C9orf72 UBQLN2
3	neurofilament cytoskeleton organization	GO:0060052	8.62	NEFH SOD1

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	dynein complex binding	GO:0070840	8.62	DCTN1 NEFH

Sources

Sources for Lateral Sclerosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia